All 14 OneOncology Partner Practices Apply to Participate in EOM
03 Oct 2022
NASHVILLE, Tenn., Oct. 3, 2022 /PRNewswire/-- OneOncology, the national platform for independent oncology practices, announced today that all 14 of its partner practices have applied to participate in Medicare's Enhancing Oncology Model (EOM), the agency's value-based care model for oncology.
Having all practices apply for EOM demonstrates OneOncology practice partners' commitment to promote health equity.
"With large and diverse patient populations combined with OneOncology's analytics and value-based care expertise, our practice partners will have the data and insights to help them successfully participate in the EOM," said Davey Daniel, MD, CMO, OneOncology. "We're proud that all OneOncology practices have applied to participate, and we look forward to working with them to them to drive high-quality, patient-centered outcomes in Medicare's value-based oncology model."
One of the key components of EOM is its emphasis on promoting health equity in cancer care. Dr. Daniel said: "Having 14 of 14 OneOncology practices apply for EOM is an important indication of our practice partners' commitment to promote health equity. It also underscores the important contribution of the oncology community to improve access to high-quality cancer care for underserved populations."
OneOncology has made significant investments in infrastructure and analytics to support practice partners in preparation for EOM participation. Additionally, clinical support via Disease Groups, Pathways, and Clinical Research will unlock differentiated solutions that will improve the quality of care for patients, improve the patient experience, and bolster OneOncology practices' success in EOM. EOM participation will set a common foundation that aligns with OneOncology's desired expansion of value-based care, and we look forward to helping our practices excel in this transition.
Still, the EOM poses certain challenges for groups relative to Medicare's prior value-based oncology model, OCM, such as increased investments needed to support additional reporting requirements, lower payments for enhanced oncology services, and mandatory downside risk.
"Throughout OCM, CMMI demonstrated its willingness to improve its payment models over time," said Dr. Daniel. "For example, CMMI made important updates to OCM risk adjustment methodology and modification of risk arrangements in response to the COVID-19 pandemic. So, we remain optimistic about opportunities to engage CMMI to promote improvements to EOM that will make the program more conducive to community oncology practices' participation."
Practices who have yet to apply now have until October 10 to submit their application to CMMI. Submitting an application does not bind an applicant to participate in EOM, but it will allow oncology practices that apply to uncover further details regarding the EOM and how they might eventually perform in the model.
About OneOncology
OneOncology was founded by community oncologists, for community oncologists, with the mission of improving the lives of everyone living with cancer. Our goal is to enable community oncology practices to remain independent and to improve patient access to care in their communities, all at a lower cost than in the hospital setting. OneOncology supports our platform of community oncology practices through group purchasing, operational optimization, practice growth, and clinical innovation. Our 850 cancer care providers care for 485,000 patients at more than 175 sites of care nationwide. To learn more, visit oneoncology.com or LinkedIn. Media Contact: Eric Hoffman | ehoffman@oneoncology.com
View original content to download multimedia:
SOURCE OneOncology
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.